NLX-112 demonstrated safety and potential efficacy in reducing levodopa-induced dyskinesia and improving motor symptoms in Parkinson disease, with additional benefits seen in patients also receiving stable amantadine.:
Source: Neurology Read More
Phase 2 Findings Support Further Development of 5-HT1A Receptor Agonist NLX-112 in Parkinson Disease
Related Posts
<![CDATA[Weighing Disease-Modifying Therapy
Discontinuation in Older, Stable Patients With MS]]>
<![CDATA[Weighing Disease-Modifying Therapy Discontinuation in Older, Stable Patients With MS]]>
